Podcasts about cholangiocarcinoma

This recording features audio versions of April 2025 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Adverse Events After Percutaneous Transhepatic Biliary Drainage: A 10-Year Retrospective Analysis ReadEndovascular Therapy versus Anticoagulation Alone for Subacute Iliofemoral Deep Vein Thrombosis ReadImprovement of Hypoalbuminemia and Hepatic Reserve after Stent Placement for Postsurgical Portal Vein Stenosis ReadSafety and Effectiveness of Yttrium-90 Radioembolization in People Living with Human Immunodeficiency Virus ReadRadiation Segmentectomy and Modified Radiation Lobectomy for Unresectable Early-Stage Intrahepatic Cholangiocarcinoma ReadComparison of Liquid with Particle Embolics in a Translational Rat Model of Hepatocellular Carcinoma: Histologic and Radiographic Responses ReadJVIR and SIR thank all those who helped record this episode. To sign up to help with future episodes, please contact our outreach coordinator at millennie.chen.jvir@gmail.com.  Host:Sonya Choe, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineOutreach coordinator:Millennie Chen, University of California Riverside School of MedicineAbstract readers:Millennie Chen, University of California Riverside School of MedicineTheodore Addo, Warren Alpert Medical School of Brown UniversityIpek Midillioglu, Western University of Health SciencesDaniel Roh, Loma Linda University School of MedicineSunil Balamurugan, Western University of Health SciencesMark Oliinik, Loma Linda University School of MedicineSIR thanks BD for its generous support of the Kinked Wire.Contact us with your ideas and questions, or read more about about interventional radiology in IR Quarterly magazine or SIR's Patient Center.(c) Society of Interventional Radiology.Support the show

What if a deadly cancer was lurking inside you, and you had no idea? Gallbladder and bile duct cancer, aka Cholangiocarcinomas, are some of the most aggressive, difficult-to-detect cancers out there. With no reliable screening tests and vague symptoms that often go unnoticed, early detection is nearly impossible. But knowing the warning signs could mean the difference between life and death. In this episode of Your Doctor Friends, we sit down with Dr. Scott Pierce, an oncologist from Lexington, KY, who treated John Schlarman, a beloved UK Football Coach and unfortunately passed away from this nasty disease. Dr. Pierce will walk us through John's story to uncover the harsh reality of gallbladder and bile duct cancer, including: ✅ Why these cancers are so difficult to diagnose early ✅ The subtle symptoms that could be red flags ✅ The shocking truth about family history and risk factors ✅ Cutting-edge research that could change the game ✅ The inspiring story of Coach John Schlarman—his battle, his resilience, and his lasting impact Connect with Us: Please sign up for our SUBSTACK so you can forward this information to all your friends inboxes! For more episodes, merch, or to send us direct messages: Website: https://yourdoctorfriendspodcast.com Email: yourdoctorfriendspodcast@gmail.com Socials: Follow @your_doctor_friends on Instagram, TikTok, and YouTube. DM or send us a voice memo—we might feature it on the show! Understanding the Silent Threat Gallbladder and bile duct cancer often go undetected until it's too late. Unlike more common cancers, these diseases don't have clear early warning signs. Many patients experience vague symptoms like unexplained weight loss, persistent abdominal pain, or jaundice. By the time these symptoms prompt a doctor's visit, the cancer may already be in an advanced stage. That's why awareness is critical—understanding the symptoms and seeking medical advice early can make a difference. Why is Early Detection So Difficult? One of the biggest challenges with gallbladder and bile duct cancer is the lack of reliable screening tests. Unlike breast, colon, or prostate cancer, there isn't a simple routine test to catch these cancers early. Many cases are only discovered accidentally—like when gallstones are removed, and cancer is unexpectedly found. For bile duct cancer, detection is even harder because symptoms often don't appear until the disease has significantly progressed. Hope for the Future While the prognosis for gallbladder and bile duct cancer is often grim, there is hope on the horizon. Researchers are working on advanced blood tests that could one day help detect cancers earlier. These cutting-edge tests analyze genetic markers and proteins in the blood, potentially giving doctors a way to spot cancer before symptoms appear. Though still in development, this research could revolutionize early detection and improve survival rates. John Schlarman's Powerful Story This episode also honors the incredible journey of Coach John Schlarman. A dedicated football coach, John faced his diagnosis with remarkable strength and determination. Despite undergoing grueling treatments, he continued coaching, inspiring his team and community with his resilience. One of his most unforgettable moments? Coaching his team to victory against Tennessee while battling serious complications from his illness. His story is a testament to the power of passion, perseverance, and the human spirit. Take Charge of Your Health Gallbladder and bile duct cancer may be rare, but when they strike, they strike hard. The best defense? Awareness. If you or someone you know is experiencing unexplained weight loss, persistent abdominal pain, or yellowing of the skin, don't ignore it. Seek medical attention, ask questions, and advocate for your health.

After a long list of health issues, Karen Humphries was diagnosed with a rare type of bile duct cancer called cholangiocarcinoma.  She was initially diagnosed in 2021 with Stage 2B gallbladder cancer, had her gallbladder removed, after which the diagnosis was changed to Stage 4 cholangiocarcinoma.  Karen underwent a two-part liver resection and a chemotherapy regimen and went into remission.  Two years later, she was again diagnosed with cholangiocarcinoma.  Her treatment included biliary stents.  Karen knows her cancer is incurable but has survived and leads a happy life.   Karen Humphries' life has been marred by numerous health-related issues.  Because of a rare genetic condition, in 2010, she had to wear a colostomy bag.  A decade later, she experienced severe vomiting, pale colored stools, an inability to eat solid foods, pain in her right-side ovaries, among others.    She sought medical attention and got a gallbladder scan.  That led to the removal of her gallbladder and a diagnosis of Stage 2B gallbladder cancer.  The diagnosis was later revised as  cholangiocarcinoma, a rare form of bile duct cancer.    Karen underwent a two-part liver resection, appendix and radical lymph node abstraction, and a six-month chemotherapy regimen with xeloda. She responded well and went into remission.   However, in 2023, after biopsies of her neck and liver, the cholangiocarcinoma returned. Doctors told her that her initial diagnosis of Stage 2B gallbladder cancer was actually Stage 4 cholangiocarinoma all along.  Her treatment included biliary stents.   Karen's cancer has been labeled ‘incurable,' but she undergoes periodic CT and PET scans, and her condition has stabilized.  She maintains an upbeat approach to life and mentors others who have been diagnosed with cholangiocarcinoma and other forms of cancer.  

Delaware's Jan Meyer has become an international leader and cheerleader for people around the world fighting cholangiocarcinoma, a leading and misunderstood cancer. Here, she gives you an excellent primer on the disease, the warriors fighting it and the race to find a cure.

On today's show:  9am-10am  Significant turnout at rally against links between University of Galway and Israeli IT We'll be speaking to a Galway Man living with bile duct cancer for world Cholangiocarcinoma day

Join A/Prof Gonzalo Sapisochin as we discuss, diagnosis, evaluation, resection and transplantation of cholangiocarcinoma in patients with PSC.

Cholangiocarcinoma is an aggressive cancer that begins in the bile ducts. While the cancer is relatively rare, affecting approximately 8,000 people in the United States each year, unfortunately, it is often undiagnosed until an advanced stage. This late diagnosis makes cholangiocarcinoma very challenging to treat, and less than 10% of patients survive for five years after diagnosis. Traditional anti-cancer treatments, such as chemotherapy, have only limited effectiveness in cholangiocarcinoma, and can cause serious side effects. Recently developed immunotherapy and targeted therapies have provided promising options for this difficult-to-treat disease. Dr. Kim Saverno of the Incyte Corporation, a biopharmaceutical company headquartered in the U.S., and the study's co-authors, have been studying the real-world use of an FDA-approved targeted drug for cholangiocarcinoma called pemigatinib. Pemigatinib was approved by the FDA in 2020. It can be specifically used for cholangiocarcinoma patients who have genetic changes in a protein known as fibroblast growth factor receptor 2, or FGFR2 for short. Their study, to the best of our knowledge, is the first to examine pemigatinib's use in real-world settings, and reveals information about treatment patterns, FGFR2 testing patterns, and effectiveness of pemigatinib for cholangiocarcinoma when used in everyday practice.

This recording features audio versions of October 2024 Journal of Vascular and Interventional Radiology (JVIR) abstracts:Outcomes Analysis of Yttrium-90 Radioembolization for Tumors Other Than Metastatic Colorectal Cancer from the Radiation-Emitting SIR-Spheres in Nonresectable (RESiN) Registry ReadOpen access: Using Voxel-Based Dosimetry to Evaluate Sphere Concentration and Tumor Dose in Hepatocellular Carcinoma Treated with Yttrium-90 Radiation Segmentectomy with Glass Microspheres ReadClinical Effectiveness of Drug-Eluting Microsphere Transcatheter Arterial Chemoembolization Combined with First-Line Chemotherapy as the Initial Treatment for Patients with Unresectable Intrahepatic Cholangiocarcinoma ReadComparison of Small-Sized (70–150 μm) and Intermediate-Sized (100–300 μm) Drug-Eluting Embolics for Transarterial Chemoembolization of Small Hepatocellular Carcinomas (≤3 cm) ReadOpen access: Technical Feasibility and Outcome of Cryoablation of Aneurysmal Bone Cysts in Pediatric Patients ReadPrimary Limb-Based Patency for Chronic Limb-Threatening Ischemia Treated with Endovascular Therapy Based on the Global Limb Anatomic Staging System ReadOpen access: Initial Outcomes of Embolization for Type II Endoleak: Comparison of n-Butyl Cyanoacrylate–Ethiodized Oil Mixture with n-Butyl Cyanoacrylate– Ethiodized Oil–Ethanol Mixture ReadTrack Sealing in CT-Guided Lung Biopsy Using Gelatin Sponge Slurry versus Saline in Reducing Postbiopsy Pneumothorax: A Prospective Randomized Study ReadJVIR and SIR thank all those who helped record this episode:Host:Manbir Singh Sandhu, University of California Riverside School of MedicineAudio editor:Hannah Curtis, Loma Linda University School of MedicineAbstract readers:Maximillion Hayama, Duke University School of MedicineLana Kamel, University of Minnesota Medical SchoolJessalyn Yam, University of Illinois College of Medicine at ChicagoSiddak Dhaliwal, University of Missouri School of MedicineJason Hoang, The Ohio State University College of MedicineAkumbir Singh Grewal, St. George University School of MedicineMillennie Chen, University of California Riverside School of MedicineDaniel Roh, Loma Linda University School of Medicine Support the showSupport the show

Delorean Ostrom was a featured runner on Season 13 of the project.  His amazing wife lost her battle with a rare cancer in January and we wanted to check in on Delorean.  He is setting some big running and fitness goals while starting a new restaurant business and raising his two young daughters.  This one is full of love and emotion and we hope if you or someone you know is going through a tough time that this conversation helps even a little. Thanks for listening.  Donate to the Cholangiocarcinoma foundation here. 

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

David Malka, MD, PhD - Providing Cutting-Edge Care for Cholangiocarcinoma: Transforming the Patient Journey

Imugene Ltd (ASX:IMU, OTC:IUGNF) managing director and CEO Leslie Chong and strategic advisor Dr Yuman Fong sit down with Proactive's Jonathan Jackson to discuss Professor Fong's expertise and the latest company developments. Dr Fong is a world-renowned cancer researcher, physician and surgeon whose clinical work has focused on OV for more than 30 years. He is the inventor of OV CF33. Imugene has dosed the first patient in its trial for bile tract cancer (cholangiocarcinoma) patients. The MAST (metastatic advanced solid tumours) Phase 1 trial has been expanded due to early responses in gastrointestinal cancers, particularly cholangiocarcinoma, using Imugene's cancer-killing virus CF33, known as VAXINIA. The trial, held at St Vincent's Hospital, Melbourne, Australia, expects to enrol 10 patients. Interim results showed positive responses in gastrointestinal cancers, including a complete response in bile tract cancer. The trial's fifth cohort of both arms has cleared and the sixth high-dose cohort is now open. Chong expressed optimism about VAXINIA's potential in bile tract cancer, highlighting the trial's advancement to higher doses to gather key data. In November 2023, the US FDA granted fast-track designation to VAXINIA MAST for bile tract cancer, enabling closer cooperation to expedite the approval process. Bile tract cancer is a rare and challenging disease, often responding poorly to immunotherapy. A recent study reported a complete response in a patient after receiving a mid-dose of IT-administered VAXINIA monotherapy, with no safety signals observed. The Phase 1 MAST trial has progressed through monotherapy dose escalation cohorts and includes a combination study with pembrolizumab. The CF33 virus, developed by City of Hope, has shown preclinical effectiveness in shrinking various cancer tumours. #ProactiveInvestors #Imugene #ASX #OTC #CancerResearch, #BileTractCancer, #Cholangiocarcinoma, #VAXINIA, #Oncology, #ClinicalTrial, #MASTTrial, #FDAFastTrack, #InnovativeTreatment, #GastrointestinalCancer, #CancerTreatment, #LeslieChong, #StVincentsHospital, #Melbourne, #Immunotherapy, #CheckpointInhibitor, #Pembrolizumab, #CF33Virus, #CityOfHope #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

Lisata Therapeutics Inc chief medical officer Kristen Buck joined Proactive's Stephen Gunnion to discuss encouraging preclinical results for drug candidate certepetide in treating intrahepatic cholangiocarcinoma (bile duct cancer). Buck explained that the study involved a mouse model with orthotopically implanted cholangiocarcinoma, separated into four treatment groups: a control group, a group receiving only certepetide, a group treated with gemcitabine, cisplatin, and anti-PD-1 immunotherapy, and a group receiving certepetide in combination with the chemotherapy and immunotherapy. The results demonstrated that certepetide significantly enhanced the effects of chemotherapy and immunotherapy, prolonging survival, reducing lung metastases, and decreasing comorbidities like ascites. Buck highlighted that certepetide targets two specific receptors upregulated on solid tumors and helps transform the fibrotic stromal barrier in cholangiocarcinoma into a conduit for chemotherapy and immunotherapy, improving drug penetration into the tumor. These promising preclinical results come on top of the ongoing BOLSTER trial, a Phase 2a study evaluating certepetide in humans with first-line cholangiocarcinoma and a secondary cohort for second-line treatment. "We believe that using our drug in combination with immunotherapy will demonstrate a significant benefit," says Buck. "Certepetide not only targets and penetrates tumors but also modifies the hostile tumor microenvironment, decreasing T regulatory cells and increasing cytotoxic T-cells to help kill cancer." For more insightful videos like this, visit Proactive's YouTube channel. Don't forget to give the video a like, subscribe to our channel, and enable notifications for future content. #LisataTherapeutics #CancerResearch #Certepetide #Cholangiocarcinoma #CancerTreatment #Immunotherapy #PreclinicalResults #Oncology #MedicalResearch #ProactiveInterviews #ProactiveInvestors #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews

An ultrasound revealed a large mass in Melinda Bachini's liver, and that led to a diagnosis of cholangiocarcinoma, a form of bile duct cancer.  Doctors removed two thirds of her liver.  Unfortunately, her cancer returned three months.  Melinda was hoping to take part in a clinical trial, but when insurance wouldn't cover a clinical trial, settled for a chemotherapy regimen.  When the chemo didn't help but left her with a bunch of awful side effects, she decided to end the chemotherapy treatment and live as long as she could.  Then she and her husband found out about another opportunity for a clinical trial, pursued it, qualified for it.  The trial led to her achieving survivorship.

PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all! In episode 44 of the Living with PSC Podcast, Host Niall McKay talks with Jesse Kirkpatrick, Ph.D., a third-year Harvard University medical student, researcher at MIT, PSC Partners board member, and family member of a person with PSC.    They discuss Dr. Kirkpatrick's research on early detection of Cholangiocarcinoma, a rare cancer for which people with PSC are susceptible. It is often difficult to treat in our population, because Cholangiocarcinoma is typically detected late in people with PSC. Kirkpatrick and others are working to develop better diagnostic and screening tests for bile duct cancers to enable earlier detection and better outcomes for patients. In 2023, he was the winner of the American Medical Association Research Challenge for his work in this area.

In this episode of SurgOnc Today, live from SSO 2024, Dr. Alex Parikh from the University of Texas – San Antonio and Chair of the SSO HPB disease site working group, and Dr. Julie Hallet from the University of Toronto, and Vice-Chair of the SSO HPB disease site working group, are joined by Dr. Ana Gleisner from the University of Colorado and Dr. Skye Mayo from the Oregon Health and Sciences University. They will be discussing two important aspects of the surgical management of perihilar cholangiocarcinoma: determining resectability as it relates to vascular involvement, and the role of neoadjuvant therapy.

In this episode of SurgOnc Today ®, Alex Parikh, MD, MPH, FACS, FSSO, from the University of Texas – San Antonio and Julie Hallet, MD, M.Sc., FRCSC, FSSO from the University of Toronto are joined by Monica M. Dua, MD, from Stanford University and Ching-Wei Tzeng, , MD, FACS, FSSO, from the MD Anderson Cancer Center. They will be discussing two important aspects of the surgical management of perihilar cholangiocarcinoma: strategies for pre-operative optimization and biliary drainage, and management of the future liver remnant. This is part one of a two-part series.

Drs. Shaalan Beg and Aparna Parikh discuss the role of ctDNA as a powerful prognostic biomarker for GI cancers, along with its impact on risk stratification and the detection of recurrence. They highlight key studies in ctDNA that were featured at the 2024 ASCO GI Cancers Symposium, including COBRA, GALAXY, and BESPOKE in CRC, as well as the promise of ctDNA testing in the preoperative detection of iCCA. TRANSCRIPT Dr. Shaalan Beg: Hello, and welcome to the ASCO Daily News Podcast. I am Dr. Shaalan Beg, your guest host for the ASCO Daily News Podcast today. I am an adjunct associate professor at UT Southwestern's Harold Simmons Comprehensive Cancer Center in Dallas. On today's episode, we will be discussing the emergence of circulating tumor DNA (ctDNA) technology in GI cancers. I am delighted to be joined by Dr. Aparna Parikh, an assistant professor of medicine at Harvard University and the director for colorectal medical oncology at the Massachusetts General Hospital Cancer Center, where she also serves as the medical director of the Young Adult Colorectal Cancer Center. Dr. Parikh will share her insights on key research on this hot topic in GI oncology that was featured at the recent ASCO Gastrointestinal Cancers Symposium.  Our full disclosures are available in the transcripts of this episode, and disclosures related to all episodes of the podcast are available at asco.org/DNpod.  Dr. Parikh, it's great to have you on the podcast today. Dr. Aparna Parikh: Thanks so much, Dr. Beg.  Dr. Shaalan Beg: In recent years, it has become evident that liquid biopsy and other emerging ctDNA technologies are changing how we treat GI cancers, and colorectal cancer (CRC) is in the forefront of this space. Before we dive into key studies, can you briefly highlight for our listeners how ctDNA is advancing the field and how it can influence the care that we deliver to our patients in the future? Dr. Aparna Parikh: Absolutely, ctDNA is certainly a hot topic. What we have learned over the years is that ctDNA has emerged across many solid tumor types as one of the most powerful, if not the most powerful, prognostic biomarker we have to date. ctDNA has improved risk stratification. We have learned a lot about the role in what is called minimal or molecular residual disease in patients with early-stage disease, and ctDNA being a biomarker of recurrence for those patients, with ctDNA, we have a better understanding of tumoral heterogeneity, both spatially and temporally, getting a better glimpse of what is happening in a given patient with multiple metastases, as well as genomic evolution of tumors over time. So certainly many, many roles and areas where ctDNA is emerging. Dr. Shaalan Beg: This was a hot topic at the 2024 ASCO GI Cancers Symposium, and we're going to take a deep dive into some of the abstracts that were presented. Let's start with the COBRA study, which is the NRG-GI005. That was Abstract 5 at the ASCO GI Cancers Symposium, and the GALAXY study, which was Abstract 6 at the symposium. So, the COBRA study reported results of ctDNA as a predictive biomarker in adjuvant chemotherapy for people with colon cancer. At a high level, it was a negative study, but there are some important lessons for us to learn. Similarly, in the GALAXY study, investigators from Japan presented an updated analysis on the correlation of ctDNA dynamics with outcomes in colorectal cancer with minimal residual disease. How do you synthesize all this information and help the listeners understand our current state for ctDNA applications in colorectal cancer? Dr. Aparna Parikh: Yeah. Let's take the COBRA study first. Let's talk a little bit about the design of COBRA. COBRA was intended to look at patients that were resected, stage 2 colorectal cancer patients, or colon cancer patients who were 2A. These are patients where the treating physician would, at the outset, decide that there was no adjuvant chemotherapy indicated. These are patients where active surveillance would be entirely appropriate as the standard of care. Patients were randomized to arm 1, which was active surveillance, or randomized to arm 2, which was assay-directed therapy. If there were ctDNA positive in arm 2, then they were given chemotherapy, FOLFOX or CAPOX. And if they were “ctDNA not detected,” then they would also go on to active surveillance.   And so, the plan was that nearly 1,500 patients are to be recruited, and at the time of this data cut, they had around 630-some patients. The primary objective was to look at the clearance rates of ctDNA between the ctDNA-positive cohorts, remember, the chemotherapy and the active surveillance cohorts at 6 months. They had around a 5% detection rate of ctDNA patients. Ultimately, that was around 16 patients. The reason that the study shut down was that what they found was that in the surveillance arm, the arm that was not getting any treatment, they had a ctDNA clearance of 43% versus 11% in the chemotherapy arm. They had an interim analysis to look at the clearance rate between the 2 arms, and what was surprising to the investigators and the community was what was happening in terms of clearance. Why do we have a 43% clearance rate in patients that were not getting anything? And so, because of that, the study was shut down as it did not meet its prespecified interim look at clearance in those 2 arms.   Many things came up in terms of learnings from COBRA. Number one was the characteristics of the assay. And so, you take an assay in a low-risk patient population that has a fixed specificity, and when your baseline prevalence of recurrence is so low, for example, in low-risk stage 2 patients, your composite predictive value is very susceptible to small changes in that specificity. And so, your PPV is going to be a lot lower in a low-risk patient population than a higher-risk patient population. The COBRA study used an older version of a tumor-uninformed assay, so it definitely called into question some characteristics of the assay. Is one-time-point clearance sufficient, and is that the right endpoint? We have seen now, including the GALAXY study that we'll talk about here, previously reported just spontaneous clearance happening in 5%, 10% of patients. The question with that spontaneous clearance is: Was it actually clearance, or was chemotherapy just perhaps in a low ctDNA shedding state? Are you just suppressing the ctDNA below the level of limited detection?  And then in this study, the clearance draw was actually done in the chemotherapy arm right before the last cycle of chemotherapy, again to that point of, are you just suppressing the ctDNA with chemotherapy? There is also stochastic sampling error that can happen in patients with very low residual tumor volume. So, I think this is a disappointing study in the sense that it is still a really important question. There are still 2A patients that recur, but maybe [this was] not the right test, or maybe single-time-point testing wasn't enough. And so, lots of lessons to be learned from this study in terms of test and design, but hopefully more to come. I think certainly stage 2 patients remain an area where I think, hopefully, ctDNA still plays a factor for those patients.  Dr. Shaalan Beg: And how was the patient population for the GALAXY study? That was Abstract 6, compared to the COBRA study. Could you summarize those findings for us?  Dr. Aparna Parikh: Yeah, so GALAXY was part of a large study in Japan that includes an observational cohort plus therapeutic cohorts as well. And so, GALAXY was just further reporting of the observational cohort. So unlike COBRA, which is a low-risk, stage 2 study that was actually asking that interventional question: Can you use it to guide therapy? The GALAXY and the updated GALAXY just continues to show more clinical validity data rather than clinical utility data. And it was nearly 3,000 patients, pan stages. Again, the lion's share were stage 2 and 3 patients, but there were also stage 1 and stage 4 patients as well. And what they showed was that ctDNA is undoubtedly prognostic. They showed very consistent Kaplan-Meier curves, which we've seen time and time again, where if you're ctDNA-positive, you don't do as well.  What they showed was, not surprisingly, with longer-term follow-up – this is 24-month follow up, so longer-term follow up than was published in their paper last year – was that when you test at one time point, so landmark testing, the sensitivity of detecting recurrence was around 48%, and that fell from the publication last year which was around 58%, 59%, which is not surprising as you follow more people. I think single time point testing soon after surgery may miss those late recurrences, but it's still prognostic and showed a specificity of around 94%.   They also continued to show that if you continued to test with serial testing, your sensitivity improves, but what was really interesting and new, what they presented this time, was a clearance analysis. And showing, again, comparable to COBRA, in many ways, in the sense that clearance can be a little bit finicky, especially at one time point, is what they showed is that patients who had sustained clearance, and these are patients that had at least two time points with their ctDNA remained to be negative, they did very well. But if you had transient clearance, and again, the definition was a little bit broad, at least having one negative and then one positive, those patients ultimately, at 24 months, the curves came together with the no clearance curve. So initially, they did better than the people that didn't have any clearance. But if you transiently cleared at two years, the curves came back together.   And what was interesting is that in those patients that sort of transiently clear by 9 to 12 months, 80% of those are actually having a rapid return of ctDNA. And so this begs the question of was chemotherapy just suppressing that ctDNA or maybe if you have a better test you could have actually improved it.  These were some of the updated, interesting learnings from GALAXY, which remains incredibly prognostic. And then the concept of clearance, which I think we have to look into a little bit more as a field, and understanding that maybe just one time point clearance isn't sufficient.  Dr. Shaalan Beg: Yeah, and one of the most important applications for ctDNA can be its ability to inform adjuvant chemotherapy. Its ability to not only identify more people who may benefit from chemotherapy, but maybe even identify people who don't need chemotherapy. And along those lines, Abstract 9, the BESPOKE study, looked to understand the role of ctDNA-based detection of molecular residual disease to inform adjuvant therapy for stage 2 and 3 colorectal cancer. And they presented interim data at the GI ASCO this year. What were your takeaways from this study? Dr. Aparna Parikh: Exactly. Beyond the prognostic implications, I think what was really interesting was that there was the initial data looking at the benefit of adjuvant chemotherapy. So, what they did was they said, “Okay. We're going to take the MRD-positive patients and look at the benefit of adjuvant chemotherapy and then the benefit of adjuvant chemotherapy in the MRD-negative patients.” And again, remember, this is a prospective observational study, so it's not looking at negative and positive to guide therapy, but it's just looking prospectively and observationally at how those patients are doing. But what they showed again is that indeed, in the adjuvant chemotherapy group, the benefit of adjuvant chemotherapy again with the follow-up to date on the study was different in the MRD-positive patients.  First of all, I guess taking a step back, the DFS in the ctDNA-negative patients at 2 years was very good. So negative patients had over 98% 2-year DFS in both the adjuvant chemotherapy and observational group. And there was no real difference between adjuvant or not. But in the positive patients, not surprisingly, the DFS was worse. But what was reassuring to see is that you can make an impact with adjuvant chemotherapy in the positive patients. And the difference in DFS between the positive and negative patients, with adjuvant or not, was 42% versus 12.5%, in the observational patients. So, it is benefitting the patients who are positive so it does give us more data that, again, at least in the positive patients, you may be able to reverse the recurrences there with adjuvant chemotherapy. And maybe if you're negative, eventually, we'll get to a point of de-escalation of care. Again, keeping in mind the kinds of sensitivity limitations as well.  Dr. Shaalan Beg: Wonderful. And one of the other malignancies in the GI space where precision therapies and molecular biomarkers are making a huge difference are intrahepatic cholangiocarcinoma. Genomic profiling using ctDNA is increasingly being used in this population to inform precision oncology approaches and determine mechanisms of resistance to targeted therapies as well. In Abstract 528, investigators looked at the role of preoperative ctDNA testing for resectable intrahepatic cholangiocarcinoma. What are your thoughts on that study?  Dr. Aparna Parikh: Yeah, it's such an important area, as you mentioned, in the metastatic space – FGFR, IDH1, all these alterations that are emerging in intrahepatic cholangios. This was a very small study, it was preoperative, and so the tumor was intact, and around 14 patients. They used a tumor-informed approach just for detection and quantification of ctDNA. So this was not a study that was looking at a next-generation sequencing approach where you're going to actually be able to detect the alterations, but it's actually looking for the detection and quantification of ctDNA rather than genomic characterizations. And patients had about a month or so where they had their baseline blood detected. And I think what was reassuring to say was that ctDNA was actually detected in all the patients with the primary tumor intact, except for one patient who was a very low-risk stage 1A patient. There was some correlation, against a small number of patients, between the concentration of ctDNA in patients that had the lower stage and then the higher stage groups. Small numbers were actually hard to characterize and correlate with recurrence or mortality, but at least, some correlation with pathologic tumor size, they were able to because it was a bespoke panel and you're sampling the tissue and then looking in the blood, IDH1 and 2 were mutations that were tracked based on the genomic profiling and a couple of the patients were able to have their IDH mutations tracked.  So it gives us a sense, a little bit, that ctDNA, we know has a lot of variable shedding across disease states and tumor locations, but gives us some promise that it is reliably detected with the tumor-informed approach, at least preoperatively in cholangios. So may again open some more opportunities for MRD testing in cholangiocarcinoma as well.  Dr. Shaalan Beg: Thank you. That's a wonderful review of ctDNA applications in gastrointestinal cancers from the 2024 ASCO GI Cancers Symposium. Thank you, Dr. Parikh, for sharing your valuable insights with us on the podcast today. Dr. Aparna Parikh: Thank you so much for having me. Dr. Shaalan Beg: Thank you to our listeners for your time today. You'll find links to the abstracts discussed today in the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts.   Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.   Find out more about today's speakers: Dr. Shaalan Beg @ShaalanBeg Dr. Aparna Parikh @aparna1024   Follow ASCO on social media:  @ASCO on Twitter  ASCO on Facebook  ASCO on LinkedIn    Disclosures: Dr. Shaalan Beg: Employment: Science 37 Consulting or Advisory Role: Ipsen, Array BioPharma, AstraZeneca/MedImmune, Cancer Commons, Legend Biotech, Foundation Medicine Research Funding (Inst.): Bristol-Myers Squibb, AstraZeneca/MedImmune, Merck Serono, Five Prime Therapeutics, MedImmune, Genentech, Immunesensor, Tolero Pharmaceuticals   Dr. Aparna Parikh: Consulting or Advisory Role (An Immediate Family Member): PMV Consulting or Advisory Role: Checkmate Pharmaceuticals, Guardant Health, Foundation Medicine, Abbvie, Value Analytics Labs, Bayer, Taiho Oncology, Delcath, Seagen, CVS, SAGA Diagnostics, Scarce, Illumina, UpToDate, Takeda, AstraZeneca, Takeda, Pfizer, Kahr, Xilio Therapeutics, Sirtex Research Funding: PMV Pharma, Erasca, Inc, Syndax Research Funding (Institution): Bristol-Myers Squibb, Genentech, Guardant Health, Array, Eli Lilly, Novartis Pharmaceuticals UK Ltd., PureTech, Mirati Therapeutics, Daiichi Sankyo, Karkinos Other Relationship: C2i Genomics, Xgenomes, Parithera, Cadex

In today's recap episode, dive into the complexities of aligning your real-life personality with your online presence. Discover the power of individuality in social media, the challenges of standing out, and the importance of authenticity. Lesley and Brad will help you learn to embrace your uniqueness and overcome the fear of criticism while being true to yourself.If you have any questions about this episode or want to get some of the resources we mentioned, head over to LesleyLogan.co/podcast. If you have any comments or questions about the Be It pod shoot us a message at beit@lesleylogan.co. And as always, if you're enjoying the show please share it with someone who you think would enjoy it as well. It is your continued support that will help us continue to help others. Thank you so much! Never miss another show by subscribing at LesleyLogan.co/subscribe.In this episode you will learn about:How to shift perspectives to conquer fears and limiting beliefs on social media. The importance of owning and expressing your unique opinions online.How being true to yourself is crucial for creating genuine content and connections.How authenticity fosters genuine content and deeper connections.How personal engagement boosts your social media influence and presence.Episode References/Links:OPC Summer CampOPC Reformer Accountability ChallengeThe Barrels DeckCambodia Early BirdTavi Active Lesley Discount Codes: LESLEY for 20% off their purchase site-wide LESLEY30 for 30% off SALE items ONLY from any brandsChelsea Peitz WebsiteChelsea Peitz 3 Steps to Instagram SuccessWhat to Post Book by Chelsea Peitz  If you enjoyed this episode, make sure and give us a five star rating and leave us a review on iTunes, Podcast Addict, Podchaser or Castbox. DEALS! Check out all our Preferred Vendors & Special Deals from Clair Sparrow, Sensate, Lyfefuel BeeKeeper's Naturals, Sauna Space, HigherDose, AG1 and ToeSox Be in the know with all the workshops at OPCBe It Till You See It Podcast SurveyBe a part of Lesley's Pilates MentorshipFREE Ditching Busy Webinar  Resources:Watch the Be It Till You See It podcast on YouTube!Lesley Logan websiteBe It Till You See It PodcastOnline Pilates Classes by Lesley LoganOnline Pilates Classes by Lesley Logan on YouTubeProfitable Pilates Follow Us on Social Media:InstagramFacebookLinkedIn  Episode Transcript:Brad Crowell 0:00  She's arguing for, you know, having and owning your own opinion and that's actually a way to overcome your limiting belief and that's also a little bit scary.Lesley Logan 0:10  Oh, yeah. So if you're a tulip, so first of all, everyone's going to try to chop you down. I'm just going to tell you right now.Brad Crowell 0:14  Oh, everyone wants to be a tulip or should be a tulip?Lesley Logan 0:17  No, no one'sBrad Crowell 0:18  Tulips, they all grow even, right? Lesley Logan 0:19  Yeah, they grow even. Brad Crowell 0:20  Yeah. Okay. Lesley Logan 0:21  So.Brad Crowell 0:22  Fuck those tulips.Lesley Logan 0:23  Don't be a fucking tulip. Welcome to the Be It Till You See It podcast where we talk about taking messy action, knowing that perfect is boring. I'm Lesley Logan, Pilates instructor and fitness business coach. I've trained thousands of people around the world and the number one thing I see stopping people from achieving anything is self-doubt. My friends, action brings clarity and it's the antidote to fear. Each week, my guest will bring bold, executable, intrinsic and targeted steps that you can use to put yourself first and Be It Till You See It. It's a practice, not a perfect. Let's get started.  Welcome back to the Be It Till You See It interview recap where my co-host in life, Brad, and I are going to dig into the authentic convo I had with Chelsea Peitz in our last episode. If you haven't yet listened to that interview, feel free to pause this now and go back and listen to that one and then come back here and join us or listen to this one and then it will probably roll into the next one. So there you go. Brad Crowell 1:27  Yeah, there's an FYF in the middle somewhere, you know, come hang out.Lesley Logan 1:30  Something like that. Okay, so today, if you're listening to this on the actual day we drop it, is February 15th 2024. And here we go. We got a few. It's St. Skeletor's Day, which is basically the opposite of Valentine's Day. The day was created in 1998 by British comedian Richard Herring. In his words, St. Skeletor's Day is “a day for all the lost souls who don't have anyone to love,” and it is “devoted to the destruction of love.” Wow, Brad.Brad Crowell 1:59  It's become a thing. I just thought it was amazing because Masters of the Universe. It's alsoLesley Logan 2:05  World Cholangiocarcinoma Day, which is a type of cancer that develops in the bile ducts and around the liver, also affects the gallbladder. Brad Crowell 2:16  We have to actually say it right. Cholangiocarcinoma.Lesley Logan 2:22  Cholangiocarcinoma. Yeah,Brad Crowell 2:23  Yeah, so World Cholangiocarcinoma Day. (inaudible) Cholangiocarcinoma. Lesley Logan 2:31  I'm like it's CholaBrad Crowell 2:34  World Cholangiocarcinoma Day. Lesley Logan 2:36  Okay, (inaudible) to all the cholas out there. I'm apologize. I apologize.Brad Crowell 2:42  I had never heard of this. And I just thought this was something that we should bring up. It's actually a type of cancer that affects the liver and the bile ducts and the gallbladder. So. Lesley Logan 2:53  I don't even know how to get that checked you guys, but Brad Crowell 2:55  No, it's actually really hard to identify. Lesley Logan 2:57  Okay. Awesome.Brad Crowell 2:59  But today's the day to raise awareness about Cholangiocarcinoma. And finally Lesley Logan 3:04  World Hippo Day. Brad Crowell 3:06  It's World Hippo Day, y'allLesley Logan 3:07  Celebrates the extraordinary hippopotamus and encourages people to take action to prevent its extinction. Did you know that before 1909, scientists placed hippos in the same groups as pigs, despite their outward similarities with pigs or wild boars. Hippopotamuses. Why is that the plural? Brad Crowell 3:24  Hippopotamuses. Lesley Logan 3:24  Are closely related to whales, okay, dolphins and porpoises. Hippos are semiaquatic mammals that are native to sub-Saharan Africa. Okay, um, I'm gonna tell you a hippo story. Brad Crowell 3:34  Tell me a hippo story. Lesley Logan 3:35  So my ba, my, my high school, my high school, my college roommate and I, we decided to go down to San Diego and like party like it's 1999. Brad Crowell 3:45  Probably was.Lesley Logan 3:46  No. Oh, my God, I'm not that old. So this is like 2005, 2006 We got a hotel room and we like, went out to State Street and got way, way too drunk. And we wasted our hotel room. By the way, we almost made it to Mexico because we missed our exit. So just so you know.Brad Crowell 4:08  Don't drink and drive. Lesley Logan 4:09  Clearly. So we got to our hotel room, we woke up and San Diego is a really healthy place. And when you are hung over you want Taco Bell and there's none. So we went to the zoo.Brad Crowell 4:21  Really struggling to understand. Okay. Zoo.Lesley Logan 4:24  Going to the zoo.Brad Crowell 4:25  Okay. It's coming around.Lesley Logan 4:26  And we're at the zoo, and we're walking around this beautiful sunshiny day and everything is healthy, which is like the worst. And there is the hippos. And when you go to the hippos in the San Diego Zoo. You can, you go lower, so you're like at the level of the pool. So you could see the hippo swimming. Okay, so the hippo is swimming which, by the way, when a hippo swims, it's like a Volkswagen Bug. With limbs. It's so fucking huge. And it's swimming and swimming. And she swims by the glass and she's like, up against the glass with her body like elephant, elephant-type body swimming, right? And the kids are just screaming which hangover Stephanie and LL are like, what in the frickin' world. Then the hippo puts her butt up on the glass and takes a massive dump. And it's just shit hitting the glass. (inaudible) Brad Crowell 5:22  In front of all the kids.Lesley Logan 5:23  And the kids go from like, to just crying-screaming. I laughed so hard. I fucking cried. Cried, cried. I cried. And I looked at that hippo and I was like, I see you. And I, I love it. You cannot tell me that hippo didn't know what she was doing. She know what she was doing.Brad Crowell 5:46  I love how Taco Bell made it into that story.Lesley Logan 5:49  They don't sponsor this. So. Brad Crowell 5:51  World Hippo Day.Lesley Logan 5:53  Everyone. (inaudible) to pronounce.Brad Crowell 5:55  Moving, swimming right along. Lesley Logan 5:57  Swimming right along, we have OPC summer camp, you are going to go to opc.me/workshops to make sure you don't miss out on the earlybird on that. And we're going to have tons of workouts, tons of workshops, it's going to be super, super fun. You can also, while the OPC reformer accountability challenge has technically wrapped for those who did it live, you can actually sign up for it anytime at opc.me/challenge That link will actually work also in the future because it will always be there and we'll be adding another challenge in March with the mat. So if you're wanting to know how to make habit stick if you want an accountability around this, go to OPC.me/challenge. Here's what's so fun. Okay, so shout out to Alicia Lavender. She posted herself doing her 10-minute reformer at the end of her workday, and we know how much Alicia works and and she like was doing the workout. Anyway, someone else, someone else posted themselves like, like 10 minutes later. And they did the workout. And they literally said I saw Alicia do it. And so I was like, well, I better fucking do it. Because if Alicia did it then I better do it. So shout out to Life and Grip Socks because she was peer pressured into a 10-minute workout. But that's what the, that's what this workout is all about.Brad Crowell 7:13  That's what a community is about. Guilting you into movement.Lesley Logan 7:15  Peer pressure.Brad Crowell 7:16  All right.Lesley Logan 7:16  Now, accountability. So opc.me/challenge is gonna give you the accountability and the tips for creating habits that stick and you can apply them to everything else. So then next up is another waitlist, which is for the Barrels Deck and we are really, really excited. It's coming really, really together. I finally got the last barrel. It's hot pink. Brad Crowell 7:37  Oh, yeah. Lesley Logan 7:38  If you're watching on YouTube, that hot pink.Brad Crowell 7:41  Oh, yeah. Lesley Logan 7:41  That hot pink. It's so hot pink. It's so hot pink. It's so amazing. Um, so you want to go to opc.me/flashcardwaitlist that's gonna get you on the waitlist for the next deck, which means you get the best deal. Why? Because you are patient as fuck, because you're gonna wait several months for them to ship but you got the best deal. So that's where you want to go. And then lastly, we closed out the earlybird for the Cambodia retreat. And we are recording this in the past for the future. So we don't actually know how many spots are left as we record this, but you can go to Lesleylogan.co/retreat. Singular. And if there are spots left, it will let you sign up and if there are not spots left Brad Crowell 8:21  Get on the waitlist for the next year.Lesley Logan 8:23  Yeah, you know, all of this to say the moral of this story is get on waitlist because you don't miss out on shit. Brad Crowell 8:29  It's how we do it. Lesley Logan 8:30  All right, before we get into the amazing Chelsea Peitz, who I just frickin love, she's adorbs. Do we have an audience question?Brad Crowell 8:36  We do. Laurie from YouTube says why do we flex our ankles on the roll-up. It's a lot easier for me to get a stretch in my hamstrings if I point mine while I'm doing the roll-up. So what's up with flexing our ankles y'all? Lesley Logan 8:51  Thank you for your awesome question. The roll-up is not about stretching your hamstrings so flex them because when you flex your ankles, you can dig your heels down and activate those hamstrings and your back muscles so that you can actually roll up without your legs lifted off the ground and you can stretch your entire back body. So little bit of active static stretch on those hamstrings a whole lot of active static stretch on the back, lower back. And that's a goal of the roll up. It's not actually about stretching your hamstrings at all. If you want to do that, that single straight leg stretch, you are welcome. Brad Crowell 9:30  Enjoy. Lesley Logan 9:31  That's what it's for. So um, I am going to go live so you can see a visual about this over on our YouTube channel which is youtube.com/@onlinepilatesclasses Brad Crowell 9:45  Or you can just go to opc.me/yt Lesley Logan 9:48  Oh really? Brad Crowell 9:49  Yeah.Lesley Logan 9:49  Really use short links. Look at that. That's way better because I don't know why YouTube put an @ symbol It's so fucking weird. If YouTube is listening, I think it's weird. But yeah, we're going to do a live for my visual learners, so you can see what's going on. And also what you should be doing with your hip points so that you actually get that amazing stretch. But if you're doing that for you're switching your hamstrings, go to yoga, there's a whole different pose, and you can stretch the hell out of your hamstrings with that one. So thank you, Lauren, for your question. I hope this answer while, simple, get you thinking. Now, Brad, let's talk about Chelsea.Brad Crowell 10:22  Let's talk about Chelsea Peitz. A former real estate agent who was a, who has remarkably transitioned into a renowned keynote speaker, author and educator, Chelsea is an expert in blending social media and marketing with a unique blend of heart and humanity, emphasizing authenticity and creating genuine human connections in a digital world. Lesley Logan 10:46  She makes me so excited about anything with social media, but I just have to say she's also maybe more colorful than me, like, not in language. I mean, in the actual like, you guys, watch her on social media. Her background has more colors than me. her sweater, she has a sweater game that is just like absolutely insane. And all of this goes back to what she's talking about with being authentic because like, I have also followed her and her entire family has matching sweatsuit sets not like matching each other but like the sweatshirt and the sweatpants match. And they all like that's what they wear is like matching sweats set. And I think it's so cute.Brad Crowell 11:25  Well, you got yours and I, you got yours from aLesley Logan 11:31  I've a matching sweat set? Brad Crowell 11:33  You were just wearing it today. Lesley Logan 11:34  Oh my Tavi. Brad Crowell 11:35  Yeah. Lesley Logan 11:35  Oh, fuck you guys. Okay, this, let's just go to taviactive.com and use Lesley. L-E-S-L-E-Y one five. You're not going to regret this sweat suit. My matching sweat suit, fucking awesome, softest shit in the world. It's gonna be my new flying outfit. I'm obsessed, I think of you the other color. Brad Crowell 11:54  Or you could do what Brad did and open a box from 20 years ago, where I have a full Puma velour jumpsuit. Matching top and bottom y'all. Lesley Logan 12:07  Oh, you guys (inaudible) back and then hold on. But did he wear that on Saturday? No. What did he wear? He wore this like polyester blue with like weird, not even herringbone, not gingham, not plaid. I don't even know what you call the print on this thing.Brad Crowell 12:25  It's called Epic. That's what it's called.Lesley Logan 12:27  It looks like something off of that 70's show. You guys he wore it with burgundy sweatpants. So that 70's show shirt that should have been only worn in a really bad pool outfit like p ool, like going to play pool at a bar with with sweat pants his brother bought them a couple of years ago at Christmas time. And then Brad Crowell 12:47  I found that shirt in the box too. Lesley Logan 12:48  And then he met me out in public. And to make this outfit look a little bit better. He zipped up a hoodie over it. And I was like, you know, I don't match a lot. But I don't. I don't know. (inaudible)Brad Crowell 13:03  Slaying. Lesley Logan 13:04  So, okay, let's talk about Chelsea though. Brad Crowell 13:05  Let's talk about Chelsea. Lesley Logan 13:07  I love that. She said her focus on overcoming limiting beliefs and to be and to be completely transparent. That's her focus. And so she struggled with crippling anxiety with OCD her whole life since she was six years old.Brad Crowell 13:20  I'm super glad we're talking about this because I was really surprised to hear her mention this and how she turned that into a (inaudible).Lesley Logan 13:28  Yeah, she thought being vulnerable in a public space was terrifying. And she had the biggest fear of being trolled. And we talked in person in Nashville and like she totally got trolled. And, and like so her biggest fear. That's why your fears are gonna come true. Her best tip about limiting beliefs and why we have difficulty showing up online as our true selves is our perspective. Oh my God, you guys change your perspective, change your view and like, you can overcome some like you can come overcome your limiting beliefs on those things. It's really kind of amazing. Brad Crowell 14:02  Well, I think it's also the scary thing is that I mean, you mentioned it before, no one wants to be, why does everyone want to be a tulip? You know, like everyone wants to make like keep the same eye like she's arguing for, you know, having and owning your own opinion and that's actually a way to overcome your limiting belief and that's also a little bit scary. Lesley Logan 14:25  Oh, yeah. So if you're a tulip, so first of all, everyone's gonna try to chop you down. I'm just gonna tell you right now. Brad Crowell 14:30  Oh, everyone wants to be a tulip or should be a tulip? Lesley Logan 14:33  No, no one Brad Crowell 14:34  Tulips, they all grow even right? Lesley Logan 14:35  Yeah, they grow even. Brad Crowell 14:36  Yeah. Okay. Lesley Logan 14:36  So. Brad Crowell 14:38  Fuck those tulips. Lesley Logan 14:39  Don't be a fucking tulip. Also they're so hard to keep alive in a vase. So why would you want to be a tulip? But the reality is, is that like, you will not have everyone agree with you always. Period. And there are people out in this world whose entire role in life is to try to chop you down so you're even with everyone else. Because they are hurting. And they can't say what they want to say because maybe they got chopped down, they have a fear of being chopped down. So she is actually saying, be yourself and share perspective. And yeah, some people are not gonna fucking like it. And Jill Coleman, we're gonna have Jill and Danny-J on the show, actually. Brad Crowell 15:21  Oh, we are? Lesley Logan 15:22  Yeah, we are.Brad Crowell 15:22  So fun. Lesley Logan 15:23  I'm so excited. But I remember her saying, like, trust yourself enough in your own comments. Like if someone happens to say, like, oh, what about this, which happens to me all the time? And it's like, especially on YouTube, they're like, you should only be breathing like this. And I'm like, that person I didn't even respond to because I'm like, that's not even true. I'm not even going to entertain you. But the truth is, is that like, also trust yourself going? Yeah, you're correct. And I wasn't thinking about that or talking about that when I said this. And that's okay. Brad Crowell 15:54  Yeah. It's different context. Sure.Lesley Logan 15:56  There are people who love, love to troll and if they're not trolling, there's also a bunch of people who say some weird stuff somebody is requesting, I wear my blue shiny pants more. So you know, there's just weirdos out there. Let them be weird. Flock and bless, but share your perspective.Brad Crowell 16:10  Yeah. Or maybe, maybe they don't like your 1970s polyester shirt that you pulled out of the box from last fall. Lesley Logan 16:16  Baby, I love you. And you never have to wear that again. Just like, I never have to wear my shiny pants for whoever this new person is.Brad Crowell 16:25  Well, something that I loved besides my amazing shirt. Lesley Logan 16:28  Yes. Tell me more. Brad Crowell 16:30  That Chelsea actually said is the reason that we're frustrated with our social media results, nine times out of 10, is because there's a mismatch between the human being that you are in real life and the content of your videos. There's a mismatch between who you actually are in real life and the content that you're putting out. She said we've a lot of mindset on social media that's not in the real world. And she talks, she addressed common insecurities that people face. YouTube had a really interesting conversation about the sound of your own voice, like actually the way that your voice sounds to you and then how it sounds on audio. She said she didn't watch her own videos for like, five years or something. Lesley Logan 17:16  I know, isn't that crazy? I forced myself to watch our videos, and I fucking hated every minute of it. It's fine. I don't like the sound of my voice. But I don't know. Did we talk about it in this episode, but there's like some science behind that. Brad Crowell 17:28  Yeah, she did. She said that the way that you hear yourself in your head is not actually the way that other people hear your actual voice, so. Lesley Logan 17:35  Also the way you see yourself online, by the way, I see all the things I'm like, that's wrong, what the fuck are with those clothes. Why? Why are the shorts doing that? No one says those things. Brad Crowell 17:44  Yeah and so ultimately, I mean, it also goes back to kind of what you were talking about you having your own perspective, right? Where the mismatch between your online presence and your real life, she actually said, hey, you know, the best thing you can do is be natural, right? And she said, she actually asked a question. She said, most of your social media frustrations and questions can be answered by this one specific question - what would you do in real life? This is actually your superpower, having your own opinion, being true to yourself, being yourself, answering the way that you would, in a real-life context is going to be that's going to create that authenticity that's coming across in your videos people can hear that feel that. She said, she said, here's a hypothetical scenario, if you were meeting a client, and they asked you a question within your area of expertise, would you hesitate to respond? No, you'd be like, oh, yeah, I know the answer that here is the answer. You know, and you would verbally respond. She said, some people are so afraid of the sound of their own voice, that they'll write something down and give it to somebody else to say, or they aren't going to answer it in the way that they would in real life. So you know, that like, being you is your superpower. Lesley Logan 19:02  Yes. Brad Crowell 19:03  What does, what does, what does Lesley say? You are the only one that can do the things that you do the way that you do it.Lesley Logan 19:09  I should say that because you're gonna quote it and have a video about saying it. I'm gonna say it. You are the only person who can do what you do the way that you do it. You're it. You're the only person. Also my favorite compliment in my entire life was when people met me in Australia, and they said, you know, you're totally the same as you are on social media. I'm like, yeah.Brad Crowell 19:29  I just heard it on this tour that we were just just got back from.Lesley Logan 19:31  Oh, yeah? Brad Crowell 19:32  Someone else said exactly the same thing. Lesley Logan 19:33  Yeah, I've tried really, really hard. And it's been very challenging. I'll just say, I don't have lash extensions anymore. And I usually go like do a little story every morning. And y'all I do not recognize my own fucking self. And I am doing these like little stories and I'm like, who the fuck is this? I look like Tilda Swinnie like walking down the street. But you know here we go here we are, and it's her name.Brad Crowell 20:03  Swinton. Swinnie?Lesley Logan 20:03  Tilda Swinton? Tilda Swinnie?Brad Crowell 20:06  Tilda Swinton.Lesley Logan 20:08  Tilda Swinton. She's beautiful, but I didn't know I look like her until now.Brad Crowell 20:12  Well, she also has hair that matches her eyelashes and her eyebrows. Lesley Logan 20:16  Yeah, so I don't do that. My eyebrows don't match my eyelashes. Brad Crowell 20:20  Nor your hair.Lesley Logan 20:20  Nor my hair. Shout out to (inaudible) she's like, do your eyelashes like not have any color? I'm like, no, they fucking don't. They do not. I put out lashes. That's why I got lash extensions you guys, that's why I had lash extensions, okay, because they're fucking blonde. And I look like a little bit of a mouse right now. It's fine.Brad Crowell 20:42  Babe, you look amazing, babe. You look amazing. Lesley Logan 20:44  Thanks. Everyone says I look younger. So that's nice. Like, no one's saying you look beautiful. They all say you look younger and you look brighter and you, I look more open. But no one has said stunning. I just want to point that out. To all of my lovely friends thank you for your honesty. Brad Crowell 21:02  I've told her that she looks stunning. Lesley Logan 21:04  Yes. The first words out of your mouth were wow, you look so different. Brad Crowell 21:11  That is not what I said. Lesley Logan 21:12  At Sue's finale and Stephen's finale. I will have them. I'm asking them after the show you did I walked out the room. Brad Crowell 21:20  Babe, you look beautiful, babe. You look amazing. Lesley Logan 21:21  Thank you. At any rate, um, I will just say like being yourself is your superpower. Because I am acknowledging that I look like a mole. And IBrad Crowell 21:31  I can't, I can't, I can't there's nothing I'm gonna say that's gonna win in this so Lesley Logan 21:39  I, so I do this thing. And you know what people have been going oh my God, I got my lash extensions, too and my lashes are better. And by the way, you look brighter. No one said stunning. But they've said brighter. I thank you all. At any rate, be your fucking self. Brad Crowell 21:58  All right, so finally, let's talk about those Be It Action Items. What bold, executable, intrinsic or targeted action items can we take away from your conversation with Chelsea Peitz? She said, hey, you know what, the best thing to do is to reframe how you think about the content that you're putting out there. Reframe it, in the sense that the most important content is actually not traditional content at all. It's not like writing, sending emails, it's none of that. It's your conversations. That's her argument. Right? She advised. She's She told everyone hey, engage directly and personally by commenting on their posts, sending them a DM and actually talking to them saying, hey, just want to let you know that you've really inspired me today. Thank you. Right, so actually using your voice. And she said it actually I didn't know this, but it actually trains your algorithm differently. When you post something, that person that you've been talking to, and supporting, connecting with and encouraging that person is going to see your content. So who knew that when you leave a voicemail, the content that you post might be showing up in that other person's feed. And then the real strategy is talking to people. And it's an old sales strategy from the beginning of time in sales from forever, you just have to smile and like we did last week in the laughing episode. laugh a little bit. tell jokes a little bit. It's a win. Lesley Logan 23:23  Yeah. I also love this action item, you have the permission to do what you need to do. So y'all don't have to fucking post every day. She doesn't even post everyday. She's a social media expert and doesn't post every day. So like, you are allowed to be in a situation that you're in and post what you can. And she said, if you just want to post once a week, that's how you want to do it. That's fine. It's awesome. Make it an awesome one.Brad Crowell 23:46  Make it an awesome one.Lesley Logan 23:46  So just make one awesome one. I hate, like all the social media experts out there. Like if you want to grow, you're gonna post a reel a day, go live a day, and you got to post this carousel posts like oh my God, I have an actual job to do that actually people pay me to do. I don't have time for this. And you know what?Brad Crowell 24:06  Ain't got time for that. Lesley Logan 24:07  I buy into Chelsea and I am winning. And she is fucking awesome. I just want to shout out she's got an incredible course. It's really amazing. No cookie cutter shit. You get to be your authentic self. No like do this or it's not gonna work. Like it's colorful. It's amazing. We did a quick call together and she literally was like, here's what I want you to do, this is what I want to see you do and she's amazing at it. So where is her website, Brad? You're looking it up.Brad Crowell 24:33  Yeah, it's chelseapeitz.com C-H-E-L-S-E-A-P-E-I-T-Z.com. So she's got a whole section called resources. Anyway, we'll put the link in the show notes so don't you worry but she's got a free on demand video course your three step guide to Instagram success.Lesley Logan 24:49  Yeah. And she's awesome. And she's gonna have a book coming out and we'll definitely make sure you know when that's happening and like I am justBrad Crowell 24:56  Oh, is it called What to Post? Lesley Logan 24:59  Her book is not published yet. Brad Crowell 25:01  Okay, she has she has another book called What to Post? Lesley Logan 25:03  Yeah, yeah. So at any rate, go look at that. We'll link that too, get it. Brad Crowell 25:08  Check it out.Lesley Logan 25:09  And then follow her and I promise you you will not be disappointed because I just found out about these fucking ice cream things I need to have that Brad Crowell 25:18  Ice cream things, what?Lesley Logan 25:19  Yeah, she's got a whole sweet situation that is gluten-dairy free and I am so in on that. I'm so, Chelsea I'm in. Every time I see him. I'm like (inaudible).Brad Crowell 25:29  She's gonna leave you a voicemail and your DMs now, Chelsea. Lesley Logan 25:32  Well, she knows that. We do voicemail all the time. I'm Lesley Logan.Brad Crowell 25:36  I'm Brad Crowell. Lesley Logan 25:36  Thank you so much for joining us today. How are you going to use these tips in your life? Show the fuck up as yourself is how you're going to use it. Brad Crowell 25:42  Do it.Lesley Logan 25:42  In your own perspective. Don't be a tulip and tag the Be It Pod, tag Chelsea Peitz. And until next time, Be It Till You See It.Brad Crowell 25:50  Fuck those tulips.Lesley Logan 25:54  The wheels have come off this bus. Brad Crowell 25:56  Bye for now. Lesley Logan 25:58  That's all I got for this episode of the Be It Till You See It Podcast. One thing that would help both myself and future listeners is for you to rate the show and leave a review and follow or subscribe for free wherever you listen to your podcast. Also, make sure to introduce yourself over at the Be It Pod on Instagram. I would love to know more about you. Share this episode with whoever you think needs to hear it. Help us and others Be It Till You See It. Have an awesome day.  Be It Till You See It is a production of The Bloom Podcast Network. If you want to leave us a message or a question that we might read on another episode, you can text us at +1-310-905-5534 or send a DM on Instagram @Be It Pod. Brad Crowell 26:41  It's written, filmed, and recorded by your host, Lesley Logan and me, Brad Crowell. Lesley Logan 26:46  It is transcribed, produced and edited by the epic team at Disenyo.co. Brad Crowell 26:50  Our theme music is by Ali at Apex Production Music and our branding by designer and artist Gianfranco Cioffi. Lesley Logan 26:57  Special thanks to Melissa Solomon for creating our visuals. Brad Crowell 27:01  Also to Angelina Herico for adding all of our content to our website. And finally to Meridith Root for keeping us all on point and on time. Support this podcast at — https://redcircle.com/be-it-till-you-see-it/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy

Goyal, Bishop, Kelley, and Kuhlman discuss ways to prepare patients with cholangiocarcinoma for FGFR inhibitor–related adverse effects.

Jesse Kirkpatrick, a third year medical student at Harvard Medical School talks about his research in developing an early diagnostic test for cholangiocarcinoma, a rare cancer. Read his poster here: https://www.ama-assn.org/system/files/jesse-kirkpatrick-poster.pdf Learn more about the AMA research challenge: https://www.ama-assn.org/about/events/ama-research-challenge-finals✶✶✶✶ 

Lorenza Rimassa, MD - When One Size Doesn't Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma

Lorenza Rimassa, MD - When One Size Doesn't Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma

Lorenza Rimassa, MD - When One Size Doesn't Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma

Lorenza Rimassa, MD - When One Size Doesn't Fit All: Optimising Molecular Testing and Personalising Treatment Planning in Cholangiocarcinoma

David Malka, MD, PhD - Let's Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

David Malka, MD, PhD - Let's Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

David Malka, MD, PhD - Let's Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

David Malka, MD, PhD - Let's Get Personal: Effective and Individualised Management of Targeted Therapies in Cholangiocarcinoma

Approach to workup of cholangitis, chronic cholecystitis, Gallstone Ileus, Cholangiocarcinoma including Klatskin tumor, Carcinoma of GB and Pancreas At the end some house-cleaning on iatrogenic complications of gallstone disease after ERCP and other procedures are discussed (including bile duct injury and bile leak); For SOD refer to previous episode on cholecystitis management and complications of cholecystectomy.

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

Arndt Vogel, MD - Modern Management of Cholangiocarcinoma: Sharing Evidence, Experience, and Expertise

In this episode, we review the high-yield topic of ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Cholangiocarcinoma ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

Arndt Vogel, MD - Options and Opportunities in Cholangiocarcinoma: Novel Approaches for Targeting FGFR Alterations

In this episode, we review the high-yield topic of Cholangiocarcinoma⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠from the Oncology section. Follow ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠Medbullets⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ on social media: Facebook: www.facebook.com/medbullets Instagram: www.instagram.com/medbulletsofficial Twitter: www.twitter.com/medbullets --- Send in a voice message: https://podcasters.spotify.com/pod/show/medbulletsstep1/message

This week's episode will be focusing on cholangiocarcinoma, or biliary tract cancer. We will go over the testable high yield facts on the risk factors, diagnosis, and treatment of local and advanced cholangiocarcinoma.

There's a horrible, deadly cancer that not many people know about. It's called Cholangiocarcinoma. We'll learn a lot about that today from Jan Meyer, who lost her mother to this disease, and has been fighting Cholangio herself. Jan is a retired registered nurse and was diagnosed with Stage 2B intrahepatic cholangiocarcinoma in February 2018. She underwent a liver resection and then received chemotherapy for six months. She is doing well now, and is spending her life helping to raise money and awareness for cholangiocarcinoma research -- despite being confined to a wheelchair as a result of a bad automobile accident.On May 20, Jan and her husband, Dean, will hold their 4th annual 5k, called the Quack Out Cholangio 5k Run/Walk to Crush Bile Duct Cancer, with all proceeds earmarked for research. Here are some questions we asked Janice:Q. First, let's talk about Cholangio…what are the symptoms of this disease?Q. What are some of the risk factors? Is it genetic?Q. I know that Cholangiocarcinoma is a relatively rare disease. Just how rare? Do you know how many people have it?Q. If someone is diagnosed with Cholangiocarcinoma, what's your advice? Q. To what do you attribute your apparent success in dealing with this disease?Q. Let's talk about the 5K. How can people get involved?Become a supporter of this podcast: https://www.spreaker.com/podcast/the-lean-to-the-left-podcast--4719048/support.

Content Warning: Self-harm "I'm Quatraile!" Mark, Theo, Kira, and Anna meet a mysterious captive with more secrets than she knows what to do with. But getting her free isn't going to be easy. And not just because of the horde of monsters descending on the team. There's something odd going on with the girl. Something… not quite alive.  In Memory of Betsy: This episode is dedicated to our dear friend Betsy, who recently passed away from Stage 4 Cholangiocarcinoma. Betsy was a badass, a talented writer, and a wonderful human being who we miss greatly. If you're able, please join us in donating to Betsy's ⁠⁠Go Fund Me⁠⁠ or to the ⁠⁠Cholangiocarcinoma Foundation⁠⁠. Thank you for being our friend, Betsy. ------- If you liked this episode, please leave a rating and review to help us spread the word and don't forget to share with your friends. We love friends! Subscribe to our Patreon: Head to our Patreon for bonus content you won't want to miss out on. Support the Show: Follow us on social media, buy some merch, support us on Ko-fi, and check out our Wiki by heading to our DirectMe Profile. Join us on Discord! Come hang out with the cast on The Monster's Playbook Discord server where we can discuss the latest episodes, trade theories, answer questions, and get to know you, our listeners, a little better. This week we're also featuring a promo for another actual-play podcast, The Dice Collectors. Be sure to check them out wherever you listen to podcasts. ------- Cast: Jonny Grubb as the Keeper John Wander as Mark Clayton (The Divine) Lauren Johnson as Kira Ashwood (The Initiate) and Anna Ashwood (The Protector) Miah Detjen as Theo Nessos (The Hex) This episode was edited by Miah Detjen and Lauren Johnson. Theme song by Jonny Grubb. Cover art by Gabe Schmidt. Incidental music from Epidemic Sound.

Welcome back to BOOK CLUB! The fictional worlds we build in TTRPGs can get pretty dangerous, but the people at the table should always feel safe. Jonny talks with Natalie, Keeper of the Storyteller Squad and Zoe, GM of The Writer's Room to talk about what makes roleplaying a uniquely vulnerable experience for players and GMs alike, how to make your table welcoming to all, and how working with your players to build and maintain a safe space to game can make your stories so much better In Memory of Betsy: This episode is dedicated to our dear friend Betsy, who recently passed away from Stage 4 Cholangiocarcinoma. Betsy was a badass, a talented writer, and a wonderful human being who we miss greatly. If you're able, please join us in donating to Betsy's ⁠Go Fund Me⁠ or to the ⁠Cholangiocarcinoma Foundation⁠. Thank you for being our friend, Betsy. ------- Safety Tools Resources: X-Card by John Stavropoulos The Digital RPG Consent Checklist Toolkit: The OK Check-In TTRPG Safety Toolkit by Kienna Shaw and Lauren Bryant-Monk ------- If you liked this episode, please leave a rating and review to help us spread the word and don't forget to share with your friends. We love friends! Support the Show: Follow us on social media, subscribe to our Patreon, and check out our Wiki by heading to our DirectMe Profile. Join us on Discord! Come hang out with the cast on The Monster's Playbook Discord server where we can discuss the latest episodes, trade theories, answer questions, and get to know you, our listeners, a little better. Special thanks to our guests Natalie and Zoe for joining us. Be sure to check out The Storyteller Squad and The Writer's Room wherever you get your podcasts.  ------- Cast: Jonny Grubb as the Keeper  Natalie: Keeper, The Storyteller Squad Zoe: Narrator, The Writer's Room This episode was edited by Miah Detjen and Lauren Johnson. Theme song by Jonny Grubb. Cover art by Gabe Schmidt.

Join the Surgical Oncology team from UTSouthwestern and the University of Miami as they tackle a case of intrahepatic cholangiocarcinoma along with the data guiding current treatment paradigms. Listen in as they also review recent clinical trials changing the options available for patients with this dismal biliary tract cancer. Learning Objectives:  In this episode, we review the workup and diagnostic approach to intrahepatic cholangiocarcinoma with emphasis on the role and benefits of biopsy, lymphadenectomy, operative approach, and the current treatment strategies involving chemotherapy, immunotherapy, and targeted therapies against actionable mutations. Hosts:  Adam Yopp, MD, FACS (@AdamYopp) is an Associate Professor of Surgery at the UT Southwestern Medical Center and is Chief of the Division of Surgical Oncology. He also serves as Surgical Director of the Liver Tumor Program. Caitlin Hester, MD (@CaitlinAHester) is a recent graduate of the MD Anderson Complex General Surgical Oncology fellowship and is now a new faculty member in the Division of Surgical Oncology within the Sylvester Cancer Center at the University of Miami where she specializes in surgery for cancers of the liver, pancreas, and other gastrointestinal sites.  Gilbert Murimwa, MD (@GilbertZMurimwa) is a PGY-4 Research Fellow and General Surgery Resident at the UT Southwestern Medical Center. He is studying the pancreatic tumor microenvironment and targeted therapies in the lab of Rolf Brekken within the Hamon Center for Therapeutic Oncology Research. **Specialty team application link - https://forms.gle/DwrRcMYDaP3a3LaQA Please email hello@behindtheknife.org with any questions. Please visit https://behindtheknife.org to access other high-yield surgical education podcasts, videos and more.   If you liked this episode, check out other surgical oncology episodes here: https://behindtheknife.org/podcast-category/surgical-oncology/

Frederique Penault-Llorca, MD, PhD - Setting Our Sights on Actionable Mutations in Cholangiocarcinoma: The Who, What, When, Why, and How of Testing

PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all!   In episode 35 of the Living with PSC Podcast, Host Niall McKay talks with Dr. Kidist Yimam, Medical Director of the Autoimmune Liver Disease Program at California Pacific Medical Center. She is also a member of the PSC Partners Diversity, Equity, and Inclusion Working Group. In this podcast, they discuss health inequalities in PSC, including provider bias, lack of access to care, delay in diagnosis, importance of diversity in clinical trials, and more.   "It is not unusual to hear from some of our minority patients that they've been told by other providers that PSC affects people who are Caucasian, and they shouldn't be affected by the disease, leading to a delay in diagnosis of PSC, and even putting them at risk of poorer outcomes," says Dr. Yimam.   McKay and Yimam also discuss how including a diverse group of people in PSC natural history studies will allow researchers to better understand how genetics, socio-economic factors, cultural biases, and more affect the search for treatments and a cure for PSC. To make that happen, diversity is needed within the PSC Partners Patient Registry.

Dr Goyal discusses the FDA approval of futibatinib in FGFR2-positive cholangiocarcinoma, key safety data from the FOENIX*-CCA2 trial, and the importance of biomarker testing in the cholangiocarcinoma population.

PSC Partners Seeking a Cure is pleased to present Living With PSC, a podcast moderated by Niall McKay. Each month, this podcast explores the latest research and knowledge about primary sclerosing cholangitis (PSC), a rare liver disease. From patient stories, to the latest research updates from PSC experts, to collaborations that are necessary to find better treatments and a cure, this podcast has it all!   In episode 34 of the Living with PSC Podcast, Host Niall McKay talks with Nicola Tessier, a post-transplant PSC patient, about her PSC diagnosis, dealing with symptoms, MELD score issues for PSC patients, receiving a living donor liver transplant from her brother, having children post-transplant, and much more.   "The need for a liver transplant was heavily driven by my (increased) risk for cholangiocarcinoma," says Tessier. "On paper, I looked less sick than I really was. So, the option of a living donor was a better fit for me."   She received 56% of her younger brother's liver. "It was a very special day," she says.

Featuring an interview with Professor Juan Valle, including the following topics: Immunotherapy for patients with biliary tract cancers (BTCs) (0:00) Etiology and presentation of and recent advances in the management of cholangiocarcinoma (4:18) Targeting FGFR alterations in cholangiocarcinoma and other BTCs (12:47) Spectrum and management of toxicities associated with FGFR inhibitors (19:33) Targeting driver mutations beyond FGFR (28:16) Case: A man in his early 60s with intrahepatic cholangiocarcinoma, an FGFR2 fusion and an IDH1 R132C mutation (35:53) Case: A woman in her early 60s with intrahepatic cholangiocarcinoma and an IDH1 mutation that did not respond to third-line ivosidenib (41:49) Case: A woman in her early 60s with gallbladder cancer who received first-line chemotherapy with pembrolizumab (46:15) CME information and select publications

Featuring a slide presentation and related discussion from Professor Juan Valle, including the following topics: Management of biliary tract cancers (BTCs) with targetable mutations (0:00) Management of BTCs without targetable mutations (13:59) Novel targets and treatments for cholangiocarcinoma and other BTCs (20:19) CME information and select publications